title: [Clinical benefits of anti-human IL-6 receptor antibody therapy].
abstract: Interleukin-6 (IL-6) plays pathological roles in promoting autoimmune reactions and chronic inflammation as well as destruction of bone and cartilage in rheumatoid arthritis (RA). Humanized anti-human IL-6 receptor antibody, tocilizumab, specifically recognizes human IL-6 receptor and inhibits IL-6 actions. Tocilizumab has been shown to ameliorate the disease activity of RA in the clinical trials. Tocilizuamb can be a new therapy based on the pathology of RA.
authors.affiliation: Osaka University, Graduate School of Frontier Biosciences, Laboratory of Immune Regulation.
authors.forename: Norihiro
authors.initials: N
authors.lastname: Nishimoto
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D002986:Clinical Trials as Topic; D006801:Humans; D015850:Interleukin-6 / Q000502:physiology; D019947:Receptors, Interleukin-6 / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015850:Interleukin-6; D019947:Receptors, Interleukin-6; C502936:tocilizumab